Nav: Home

Drug design strategy boosts the odds against resistance development

June 14, 2017

A new rational drug design technique that uses a powerful computer algorithm to identify molecules that target different receptor sites on key cellular proteins could provide a new weapon in the battle against antibiotic resistance, potentially tipping the odds against the bugs.

The technique, which has been validated against a drug-resistant bacterial strain, identifies compounds that target two or more receptor sites on proteins that inhibit a key cellular function. To obtain resistance to drug compounds developed with the technique, the microbes would have to simultaneously develop mutations in all the receptor pockets targeted by the drug - a challenge much more significant than developing resistance in a single receptor site.

Researchers from the Georgia Institute of Technology and Harvard University believe the technique could provide a new general approach for battling drug resistance that may potentially also be applied to cancer cells and viruses which also develop drug resistance. The research, supported by the National Institutes of Health, was reported May 19 in the journal ACS Chemical Biology.

"We have developed an entirely novel mechanism for increasing antibiotic effectiveness," said Jeffrey Skolnick, director of Georgia Tech's Center for the Study of Systems Biology. "The problem of emerging antibiotic resistance is a major health care crisis, and we think this approach could allow the rapid design of new classes of molecules that would be able to maintain their effectiveness longer, allowing us to stay one step ahead of the bugs."

Antibiotic resistance often develops when proteins - often enzymes - mutate the receptor pockets that allow the drugs to bind to the protein. Bacterial populations often include individuals that have these mutations randomly, and when antibiotics kill off the susceptible cells, the population of those with the specific mutation grows. In order to control these resistant bacteria, doctors must employ a drug compound that targets a different receptor or different binding site on a key bacterial protein.

The technique identified three classes of inhibitor drugs that targeted both primary and secondary receptor pockets on the dihydrofolate reductase (DHFR) enzyme in a drug-resistant strain of Escherichia coli (E. coli). DHFR is necessary for the synthesis of important cellular building blocks, and is a classical target for antibiotics. Without production of these compounds, bacteria cannot reproduce.

Using their algorithm, Skolnick and his Georgia Tech collaborators identified 10 potentially useful drug compounds and prioritized compounds from the three categories - stilbenoid, deoxybenzoin and chalcone family of compounds - for their ability to target a secondary receptor pocket. Interestingly, one of the molecules was resveratrol which is found in red wine and which has been reported to have anti-aging and anti-cancer effects. In the laboratory, the researchers confirmed that the commercially available compounds could indeed bind with DHFR.

But the real test was whether the compounds would work on living bacteria. To evaluate that, the Georgia Tech researchers worked with Eugene Shakhnovich, a professor in the Department of Chemistry and Chemical Biology at Harvard University. Shakhnovich and his colleagues confirmed that the drug compounds shut down the production of folates in the drug-resistant E. coli, dramatically slowing the growth of the bacterium. They also showed that the addition of folates to the bacterial population allowed the bugs to survive despite treatment by the DHFR-inhibiting drugs.

"We tested the compounds in vitro with purified variants of the enzyme," Shakhnovich said. "We engineered E. coli strains that carry escape mutations in the folA locus - which encodes DHFR - on their chromosomes and proved that the newly-found compounds effectively inhibit growth in both wild-type and escape mutant strains of DHFR, albeit at high concentrations."

Because it is a relatively small protein with well-defined biophysical properties, DHFR "represents a desirable model to explore the genotype-phenotype relationship between biophysical properties of the enzyme and the fitness and evolution of a microorganism," Shakhnovich added.

As a next step, Skolnick would like to test the principle on other proteins essential to other microorganisms to see if two or more binding pockets can be targeted. That could require development of new therapeutic molecules able to attack the microbial targets. Ultimately, the technique could be used to shut down other avenues of antibiotic resistance, including the ability of cells to break down drugs or eject them before they can bind.

If the technique proves successful in other laboratory studies, testing with an animal model would be necessary to determine whether it can be beneficial in living organisms.

DHFR has been targeted for anti-cancer drugs, and Skolnick is hopeful that the two-receptor technique may prove useful in developing new chemotherapy agents that could fight off the resistance that often renders them useless.

Skolnick believes the approach may help scientists stay ahead of bacterial resistance by providing a technique to rapidly develop new drugs. The compounds would be used in combination therapies to further guard against development of resistance.

"We are always going to be at war with microbes," he said. "The bacterial system is going to evolve to respond to new antibiotics, so we have to keep targeting something else so the system never gets to evolve resistance. It's likely that we'll need to use combination therapies that use multiple drugs to eliminate the development of resistance."
This project was funded by 1R35GM118039 and 1RO1068670 (to Shakhnovich) of the Division of General Medical Sciences of the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CITATION: Bharath Srinivasan, Joa?o V. Rodrigues, Sam Tonddast-Navaei, Eugene Shakhnovich, and Jeffrey Skolnick, "Rational Design of Novel Allosteric Dihydrofolate Reductase Inhibitors Showing Antibacterial Effects on Drug-Resistant Escherichia coli Escape Variants," (ACS Chemical Biology, 2017)

Georgia Institute of Technology

Related Antibiotic Resistance Articles:

New antibiotic packs a punch against bacterial resistance
Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.
Key to 'superbug' antibiotic resistance discovered
An international study led by Monash University's Biomedicine Discovery Institute has discovered the molecular mechanism by which the potentially deadly superbug 'Golden Staph' evades antibiotic treatment, providing the first important clues on how to counter superbug antibiotic resistance.
New weapon in fight against antibiotic resistance discovered
Scientists have designed an antibiotic that could combat WHO priority pathogens by suppressing the energy supply of bacteria
Lighting up antibiotic resistance
Carbapenems are among the 'antibiotics of last resort' and can fight infections for which other drugs have long lost their effectiveness.
How to solve a problem like antibiotic resistance
There has been much recent talk about how to target the rising tide of antibiotic resistance across the world, one of the biggest threats to global health today.
Antibiotic resistance: A burgeoning problem for kids too
In a new, first-of-its-kind study, researchers from Case Western Reserve University School of Medicine have found a 700 percent surge in infections caused by bacteria from the Enterobacteriaceae family resistant to multiple kinds of antibiotics among children in the US.
'Brute force' can overcome antibiotic resistance
Antibiotics can still kill drug-resistant bacteria if they 'push' hard enough into bacterial cells, finds new UCL-led research funded by the Engineering and Physical Sciences Research Council.
Why hospital antibiotic management strategies do little to curb resistance
The team have shown that 'determining whether antibiotic cycling or mixing selects best against drug resistant pathogens is not possible, even in standardized questions using mathematical models, let alone in the clinic,' according to lead author Robert Beardmore.
Antibiotic resistance just became more complex
Bacteria that are susceptible to antibiotics can survive when enough resistant cells around them are expressing an antibiotic-deactivating factor.
The evolution of antibiotic resistance, on a plate
Researchers have developed a large culturing device to track the evolution of bacteria as they mutate in the presence of antibiotics, revealing that, surprisingly, the fittest mutants were not those most likely to infiltrate higher antibiotic concentrations.

Related Antibiotic Resistance Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".